Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb:242:108351.
doi: 10.1016/j.pharmthera.2023.108351. Epub 2023 Jan 24.

Targeting the Semaphorin3E-plexinD1 complex in allergic asthma

Affiliations
Review

Targeting the Semaphorin3E-plexinD1 complex in allergic asthma

Mojdeh Matloubi et al. Pharmacol Ther. 2023 Feb.

Abstract

Asthma is a heterogenous airway disease characterized by airway inflammation and remodeling. It affects more than 300 million people worldwide and poses a significant burden on society. Semaphorins, discovered initially as neural guidance molecules, are ubiquitously expressed in various organs and regulate multiple signaling pathways. Interestingly, Semaphorin3E is a critical molecule in lung pathophysiology through its role in both lung development and homeostasis. Semaphorin3E binds to plexinD1, mediating regulatory effects on cell migration, proliferation, and angiogenesis. Recent in vitro and in vivo studies have demonstrated that the Semaphorin3E-plexinD1 axis is implicated in asthma, impacting inflammatory and structural cells associated with airway inflammation, tissue remodeling, and airway hyperresponsiveness. This review details the Semaphorin3E-plexinD1 axis in various aspects of asthma and highlights future directions in research including its potential role as a therapeutic target in airway allergic diseases.

Keywords: Airway hyperresponsiveness; Airway remodeling; Asthma; Inflammation; PlexinD1; Semaphorin3E.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr. Abdelilah S. Gounni holds a patent (WO2012131477A1) “METHODS FOR USING SEMAPHORIN POLYPEPTIDES” The rest of the authors declare that they have no competing interests. The rest of the authors have no conflict of interest.

Similar articles

Cited by

Publication types

Grants and funding